Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Arch-incubated remyelination play Autobahn launches with $76M series B

Elizabeth S. Eaton, Staff Writer
June 10, 2020 2:09 AM UTC

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next year, has a stronger genetic rationale than competing programs.

Arch Venture Partners incubated the biotech and co-led the untranched round with Cowen Healthcare Investments. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Autobahn Therapeutics Inc.